World News – AU – Why is Kazia Therapeutics Australia’s shining star for biotech – ShareCafe

Kazia Therapeutics’ share price was driven by strong buying in US-listed ADRs as the company’s market capitalization moved from $ 75M to $ 200M since the Corporate Connect Research report was released. Corporate Connect biotechnology analyst Mark Sinatra updates the market after Kazia announces ASX for more Paxalisib data.

For full details refer to the search report below or click here to download your copy.

Corporate Connect Research Analyst Mark Sinatra has worked extensively in the life sciences industry, having worked for more than 25 years. Mark spent his time providing specialist advisory services to venture capital firms, listed and unlisted life sciences companies, providing company analysis for various uses, and investing in the life sciences sector listed on the ASX..

Everyday resource for practical investors. Market insights and investment ideas are delivered for free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 421 628 71589. All rights reserved.
No part of this website may be reproduced, copied, or released in any way without written permission.
Share Cafe is an Authorized Corporate Representative (001283561) of PacReef Asset Management Pty Ltd holding an Australian Financial Services License (Number: 488045)

Antisense Therapeutics’ flagship drug is at a link between two areas of drug development that are beginning to grow exponentially in importance.. One relates to how it works and the other to what type of drug it is. Combine that with an administration that knows the drug well and results in a trial of terrible disease in children, and you’ll have the basis for creating the true value..

Please prove that you are human by choosing the house.

Terracom has positioned itself to improve efficiency and margins as well as pursue organic growth of mines.. Cash flow will be inflated even further once the currently low coal prices recover. These assets appear to be undervalued compared to the $ 0 base case. 27 / NPV share TER valuation. TER has a positive side in management’s track record of handing over new projects from development assets currently under control and / or by opportunistic acquisition..

Please prove that you are human by choosing the house.

Since Aug. 1, Kazia Therapeutics has announced a & Fast Track case for one program of &, an orphan and rare disease medicine for children, while ending the period with the announcement of a new trial of its cancer drug, paxalisib. Over the next nine months, investors are likely to see six data readings from five programs. How fast is the company?

Please prove that you are a human being by choosing the cup.

Kazia Therapeutics, Glioblastoma, ASX: KZA, NASDAQ: KZIA, ASX